BACKGROUND Myocardial infarction with nonobstructive coronary arteries (MINOCA) occurs in 5% to 10% of all patients with myocardial infarction. Clinical trials of secondary prevention treatment in MINOCA patients are lacking. Therefore, the aim of this study was to examine the associations between treatment with statins, renin-angiotensin system blockers, β-blockers, dual antiplatelet therapy, ...

Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complications. Dual antiplatelet therapy, combining aspirin and clopidogrel, is the standard care for patients having acute coronary syndromes or undergoing percutaneous coronary intervention according to the current ACC/AHA and ESC guidelines. But in spite of administration of dual antiplatelet therapy, so...

BACKGROUND The optimal duration of dual antiplatelet therapy after percutaneous coronary intervention (PCI) remains uncertain. The objective of this study was to examine the association between duration of dual antiplatelet therapy and re-hospitalization for acute coronary syndrome (ACS) in ACS patients who underwent PCI. METHODS We identified 975 newly diagnosed ACS patients who underwent PC...

PRACTICE Alerts are consensus-based reports that address specific aspects of patient management, patient care, and patient safety. This Practice Alert reviews published recommendations that address the perioperative management of surgical patients with recently implanted coronary artery stents. The intent of the Alert is to provide the anesthesiologist with information about (1) the increased r...

The 'pill in the pocket' concept is an established therapy for atrial fibrillation. The current guidelines for the management of patients with ST-elevation myocardial infarction endorse the concept that faster time to reperfusion is associated with important reductions in morbidity and mortality. The mechanical reperfusion and outcome of these patients is significantly supported by dual antipla...

Objective: There are concerns regarding ischemic events associated with stent-assisted coil embolization. It is important to evaluate the risk factors for delayed thromboembolic events. This study evaluated risk factors after reduction to singleantiplatelet therapy 140–365 days after embolization. Methods: We conducted a retrospective and cross-sectional study of patients who underwent stent-as...

BACKGROUND To test the hypothesis that point-of-care assays of platelet reactivity would demonstrate reduced response to antiplatelet therapy in patients who experienced Drug Eluting Stent (DES) ST whilst on dual antiplatelet therapy compared to matched DES controls. Whilst the aetiology of stent thrombosis (ST) is multifactorial there is increasing evidence from laboratory-based assays that hy...

BACKGROUND AND PURPOSE Lacunar stroke accounts for ≈25% of ischemic stroke, but optimal antiplatelet regimen to prevent stroke recurrence remains unclear. We aimed to evaluate the efficacy of antiplatelet agents in secondary stroke prevention after a lacunar stroke. METHODS We searched MEDLINE, Embase, and the Cochrane library for randomized controlled trials that reported risk of recurrent s...